Zenapax humanized anti-tac monoclonal antibody targeted to interleukin-2 receptors on activated T cells data

PDLI (Mountain View, Calif.) reported Phase I data from 12 recipients of kidney transplants, with only one episode of rejection after treatment with the anti-tac monoclonal. As presented at the meeting of the American Society of Transplant Physicians in Chicago, all patients have functioning grafts nine to 12 months after surgery without further rejection episodes.

Historical data show that six of 16 patients treated comparably but without the antibody experienced rejection within six months. ...